PsiOxus Therapeutics

Business Description

PsiOxus Therapeutics is a developer of novel therapeutics for solid tumours through its proprietary targeted oncolytic virus and tumour-specific immuno-gene therapy platform (T-SIGn).

Rationale for Investment

To be a world-leading cancer gene therapy company, developing an internal programme and entering into commercial partnerships to advance a oncolytic virus pipeline.

  • The team

    Paolo Paoletti – Non-executive Chair
    John Beadle – CEO